Hiroyasu Kaneda (Sho Hiroyasu)

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 5

Top Topics

Small Cell Lung Cancer

Tyrosine Kinase

Candida Albicans

Brain Metastases

Top Venues

Investigational new drugs

Journal of cell science

International journal of clinical oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Hitomi Nakatsukasa, Masaya Takahashi, Masahito Shibano, Yusuke Ishigami, Tomoya Kawaguchi, Yasutaka Nakamura, Hiroyasu Kaneda
Clinical impact of concomitant BIO-three use in advanced or recurrent non-small cell lung cancer treated with immune-checkpoint inhibitor. International journal of clinical oncology (2024)
Hiroyasu Kaneda, Kenji Sawa, Haruko Daga, Asuka Okada, Yuki Nakatani, Shinji Atagi, Kyoichi Okishio, Yoko Tani, Yoshiya Matsumoto, Koichi Ogawa, Kenji Nakahama, Motohiro Izumi, Shigeki Mitsuoka, Tomoya Kawaguchi
Phase 1b study of ramucirumab in combination with erlotinib or osimertinib for untreated EGFR-mutated non-small cell lung cancer patients with asymptomatic brain metastases. Investigational new drugs 39 (6) (2021)
Koichi Ogawa, Hiroyasu Kaneda, Tamaki Kawamoto, Yoko Tani, Motohiro Izumi, Yoshiya Matsumoto, Kenji Sawa, Tomohiro Suzumura, Tetsuya Watanabe, Shigeki Mitsuoka, Kazuhisa Asai, Tomoya Kawaguchi
Early-onset meningitis associated with atezolizumab treatment for non-small cell lung cancer: case report and literature review. Investigational new drugs 38 (6) (2020)
Hiroyasu Kaneda, Gregory Paul Stimac, Susan B Hopkinson, Jonathan C R Jones
Loss of β-PIX inhibits focal adhesion disassembly and promotes keratinocyte motility via myosin light chain activation. Journal of cell science 130 (14) (2017)
Emi Date, Kunio Okamoto, Souichi Fumita, Hiroyasu Kaneda
Gastrointestinal perforation related to lenvatinib, an anti-angiogenic inhibitor that targets multiple receptor tyrosine kinases, in a patient with metastatic thyroid cancer. Investigational new drugs 36 (2) (2017)